Oncology Brothers: Practice-Changing Cancer Discussions Current Treatment Landscape of Ovarian Cancer with Dr. Sharyn Lewin
Oct 27, 2025
Dr. Sharyn Lewin, a leading gynecologic oncologist and Director of Gynecologic Oncology at Holy Name Medical Center, shares her expertise on ovarian cancer treatments. She emphasizes the critical role of surgical staging and debulking surgeries. The conversation includes insights on germline testing and the use of PARP inhibitors alongside bevacizumab. Dr. Lewin also discusses strategies for managing refractory disease and the importance of biomarker testing, particularly HRD status, for personalized treatment options.
AI Snips
Chapters
Transcript
Episode notes
Prioritize Surgery And Prechemo Tissue Sampling
- Do offer upfront surgical debulking when feasible because complete cytoreduction improves outcomes.
- If using neoadjuvant chemo, obtain sufficient tissue (6–8 cores) before treatment to allow HRD and NGS testing.
Test BRCA And HRD Upfront With Best Assay
- Do perform germline BRCA, somatic BRCA, and HRD testing at diagnosis to guide maintenance.
- Use a validated HRD assay (Myriad MyChoice) because other tests may miss patients eligible for PARP therapy.
Integrate Bevacizumab And PARP Based On Risk
- Start bevacizumab with frontline platinum-based chemo for many patients and continue it in maintenance for HRD-negative cases.
- For BRCA-mutant or somatic-BRCA patients, favor olaparib maintenance for two years based on SOLO‑1.